Cancer patients could avoid unnecessary radiation therapy as a result of an international clinical trial, led by Peter Mac ...

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology to optimize drug delivery for applications with significant unmet need, ...

which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis ("EoE"). New Clinical Data from the Fourth Cohort of the RESOLVE Trial The results announced ...

PP02.05 Initial Results from RESOLVE, a Phase 1b Dose-Escalation Study of EP-104GI (Extended-Release Fluticasone ...

Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission ...

CALY-002 is under development for the treatment of eosinophilic esophagitis, celiac disease and unspecified dermatological disorders. It is a fully-humanized monoclonal antibody also administered ...

Eupraxia's EP-104GI is currently in a Phase 1b/2a trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of ...

Steroid injection combined with oral steroid therapy outperformed other steroid administrations for preventing esophageal stricture post-ESD.